ArticleBMC global and public health2025
Whole genome sequencing and phylogenetic analysis of dengue virus in Central Nepal from 2022 to 2023.
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn Nepal, dengue is an emerging disease of growing concern as outbreaks are increasing in both size and geographic reach and beginning to affect areas previously thought dengue-free. Dengue genomic surveillance has previously been limited within Nepal; however, with the increase in accessibility to sequencing technologies since the COVID-19 pandemic, it has recently become more feasible.
methodsThis hospital-based retrospective study utilized banked samples from the 2022 and 2023 dengue seasons from Dhulikhel Hospital/Kathmandu University Hospital in Central Nepal. Next-generation sequencing was performed to obtain whole genome sequences of dengue virus which were analyzed phylogenetically using a maximum likelihood GTR + G model. Mutations were evaluated across viral particle region using the GISAID DengueServer.
resultsWe obtained 41 full-length sequences of DENV from 80 PCR-positive samples, including 24 sequences (58.5%) from 2022 and 17 sequences (41.5%) from 2023. We identified a shift in the majority serotype of our samples from DENV1 in 2022 to DENV3 in 2023, though 3 out of the 4 serotypes were identified in both years. Phylogenetic analysis revealed clusters within genotype III of DENV1 and genotype III of DENV3 closely related to strains from an outbreak of DENV in northern India in 2018-2019. DENV2 sequences fell into the cosmopolitan genotype IV-A1 and IV-B2 clades and were related to sequences from South and Southeast Asia and the USA, pointing to the global nature of dengue transmission. NS3 showed the highest frequency of mutation, whereas NS2B, NS4, NS5, and E were the most conserved. The most common mutations found were substitutions L17M and T20I in the 2 K peptide. A high number of mutations were observed in DENV3, followed by DENV2, with some mutations being unique to specific serotypes and others matching previously reported strains.
conclusionsWe identified possible clade shifts in the DENV1 and 2 populations and a rising prevalence of DENV3. Our study showed a high level of serotype diversity of DENV circulating in Central Nepal. Furthermore, our results indicate that DENV populations in Nepal are related to a geographically diverse set of sequences but are most strongly influenced by Indian strains of DENV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.